MENU
CLLS
AS OF
Feb 4, 02:30 PM (EDT)
Price
$3.54
Change
+$0.01 (+0.28%)
Capitalization
388.82M
35 days until earnings call
Intraday BUY SELL Signals
+Compare
CLLS
Stock ticker: NASDAQ
AS OF
Feb 4, 02:30 PM (EDT)
Price
$3.54
Change
+$0.01 (+0.28%)
Capitalization
388.82M

CLLS Cellectis SA Forecast, Technical & Fundamental Analysis

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications... Show more

Industry: #Biotechnology
CLLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for CLLS with price predictions
Feb 03, 2026

CLLS sees MACD Histogram just turned negative

CLLS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLLS as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

CLLS moved below its 50-day moving average on January 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CLLS crossed bearishly below the 50-day moving average on January 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CLLS entered a downward trend on February 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for CLLS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.531) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (4.710) is also within normal values, averaging (331.843).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CLLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

CLLS is expected to report earnings to fall 3,048.00% to -29 cents per share on March 11

Cellectis SA CLLS Stock Earnings Reports
Q4'25
Est.
$-0.29
Q3'25
Beat
by $0.24
Q2'25
Missed
by $0.02
Q1'25
Beat
by $0.07
Q4'24
Missed
by $0.07
The last earnings report on November 07 showed earnings per share of 0 cents, beating the estimate of -23 cents. With 19.04K shares outstanding, the current market capitalization sits at 388.82M.
A.I. Advisor
published General Information

General Information

a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCEMX18.740.47
+2.57%
PACE International Em Mkts Eq P
BGEWX14.210.24
+1.72%
Baillie Gifford Emer Mkt Ex Chn Instl
CBEJX10.880.02
+0.18%
Allspring Large Cap Value CL R6
FBIOX25.85N/A
N/A
Fidelity Select Biotechnology
SCPIX54.71-0.46
-0.83%
DWS S&P 500 Index S

CLLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CLLS has been closely correlated with CMVLF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if CLLS jumps, then CMVLF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLLS
1D Price
Change %
CLLS100%
-7.59%
CMVLF - CLLS
82%
Closely correlated
N/A
SLN - CLLS
43%
Loosely correlated
-1.22%
MDGL - CLLS
40%
Loosely correlated
-1.49%
PMVP - CLLS
38%
Loosely correlated
+1.89%
AXON - CLLS
36%
Loosely correlated
-1.89%
More